Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/32/43/8d/32438d12-f214-2b84-a090-4cb5c1fd55ff/mza_1588204697638323759.jpg/600x600bb.jpg

Project Oncology®

ReachMD

180 episodes

3 days ago

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Science

Medicine

RSS

All content for Project Oncology® is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

Project Oncology®

2 weeks ago

Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Wang, MD

For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.